Skip to main content

Table 2 Cohort characteristics stratified by early oral antimalarial treatment exposure

From: Association between oral antimalarial medication administration and mortality among patients with Ebola virus disease: a multisite cohort study

  Treated (n = 376, %) Untreated (n = 48, %) P-value
Age (years)* 31.2 ± 18.8 23.0 ± 15.9 0.001
Sex
 Female 223 (59.3) 30 (62.5) 0.756
 Male 153 (40.7) 18 (37.5)
Length of Stay (days) 7, (4, 12) 5, (1, 8) 0.216
Country of Treatment
 Sierra Leone 249 (66.2) 41 (85.4) 0.008
 Liberia 127 (33.8) 7 (14.6)
Rapid diagnostic test for malaria results
 Positive 45 (12.0) 3 (6.3) 0.177
 Negative 167 (44.4) 28 (58.3)
 Not Tested 164 (43.6) 17 (35.4)
Cycle threshold value /viral load
 ≥22 (Low Viral Load) 112 (29.8) 10 (20.8) 0.162
  < 22 (High Viral Load) 135 (35.9) 24 (50.0)
 Missing 129 (34.3) 14 (29.2)
Treatments received first 48 hours of care
 ORS 350 (93.1) 23 (47.9) 0.000
 Cefixime 342 (91.0) 18 (37.5) 0.000
 Multivitamins 243 (64.6) 18 (37.5) 0.000
 Ondansetron 97 (25.8) 14 (29.2) 0.604
 Vitamin C 357 (94.9) 26 (54.2) 0.000
 Zinc Sulphate 19 (5.1) 3 (6.3) 0.727
 Vitamin A 315 (83.8) 15 (31.3) 0.000
Signs & symptoms first 48 hours of care
 Abnormal Bleeding 98 (26.1) 24 (50.0) 0.001
 Coma 2 (0.5) 4 (8.3) 0.002
 Diarrhea 266 (70.7) 32 (66.7) 0.615
 Dysphagia 152 (40.4) 19 (39.6) 1.00
 Dyspnea 117 (31.1) 18 (37.5) 0.753
 Jaundice 22 (5.9) 3 (6.3) 0.754
 Anorexia 252 (67.0) 31 (64.6) 0.747
 Abdominal Pain 237 (63.0) 28 (58.3) 0.530
 Vomiting 223 (59.3) 31 (64.6) 0.534
  1. *Values represent mean with standard deviation
  2. Values represent median with interquartile range